Sumera I. Ilyas, M.B.B.S.

  1. Gastroenterologist
  2. Gastroenterologist (Transplant Hepatologist)
  3. Internist

Publicaciones

  1. Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology. 2022 Jun; 75 (6):1604-1626 Epub 2022 Apr 07
    View PubMed
  2. Alva-Ruiz R, Wu T, Idalsoaga F, Ramkissoon R, Arab JP, Ilyas SI. Hepatology highlights. Hepatology. 2022 Jun; 75 (6):1363-1364
    View PubMed
  3. Conboy CB, Penrice DD, Watkins R, Diaz LA, Arab JP, Ilyas SI. Hepatology highlights. Hepatology. 2022 May; 75 (5):1071-1072
    View PubMed
  4. Miyabe K, Chandrasekhara V, Wongjarupong N, Chen J, Yang L, Johnson S, Chia N, Walther-Antonio M, Yao JZ, Harrington SC, Nordyke CK, Eaton JE, Gossard AA, Oli S, Ali HA, Lavu S, Giama NH, Hassan FA, Ali HM, Enders FT, Ilyas SI, Gores GJ, Topazian MD, Kashyap PC, Roberts LR. Potential Role of Inflammation-Promoting Biliary Microbiome in Primary Sclerosing Cholangitis and Cholangiocarcinoma. Cancers (Basel). 2022 Apr 24; 14 (9)
    View PubMed
  5. Tomlinson JL, Ahn JC, Povero D, Ramkissoon R, Ilyas SI, Arab JP. Hepatology Highlights. Hepatology. 2022 Apr; 75 (4):775-776
    View PubMed
  6. Sun L, Wang Y, Wang X, Navarro-Corcuera A, Ilyas S, Jalan-Sakrikar N, Gan C, Tu X, Shi Y, Tu K, Liu Q, Lou Z, Dong H, Sharpe AH, Shah VH, Kang N. PD-L1 promotes myofibroblastic activation of hepatic stellate cells by distinct mechanisms selective for TGF-beta receptor I versus II. Cell Rep. 2022 Feb 8; 38 (6):110349
    View PubMed
  7. Watkins R, Ilyas SI, Penrice DD, Conboy CB, Ayares G, Arab JP. Hepatology Highlights. Hepatology. 2022 Feb; 75 (2):241-242
    View PubMed
  8. Wang J, Loeuillard E, Gores GJ, Ilyas SI. Cholangiocarcinoma: what are the most valuable therapeutic targets - cancer-associated fibroblasts, immune cells, or beyond T cells? Expert Opin Ther Targets. 2021 Oct; 25 (10):835-845 Epub 2021 Dec 03
    View PubMed
  9. Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat Rev Dis Primers. 2021 Sep 9; 7 (1):65 Epub 2021 Sept 09
    View PubMed
  10. Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs. 2021 Apr; 30 (4):429-438 Epub 2020 Dec 28
    View PubMed
  11. Rizvi S, Wang J, El-Khoueiry AB. Liver Cancer Immunity. Hepatology. 2021 Jan; 73 Suppl 1:86-103 Epub 2020 Nov 07
    View PubMed
  12. Gile JJ, Ou FS, Mahipal A, Larson JJ, Mody K, Jin Z, Hubbard J, Halfdanarson T, Alberts SR, Jatoi A, McWilliams RR, Ma WW, Ilyas S, Smoot R, Roberts L, Gores G, Borad M, Bekaii-Saab TS, Tran NH. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol. 2021; 5 Epub 2021 July 28
    View PubMed
  13. Van Treeck BJ, Lotfalla M, Czeczok TW, Mounajjed T, Moreira RK, Allende DS, Reid MD, Naini BV, Westerhoff M, Adsay NV, Kerr SE, Rizvi SH, Smoot RL, Liu Y, Davila J, Graham RP. Molecular and Immunohistochemical Analysis of Mucinous Cystic Neoplasm of the Liver. Am J Clin Pathol. 2020 Nov 4; 154 (6):837-847
    View PubMed
  14. Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O'Brien D, Wang C, Graham RP, Smoot RL, Dong H, Ilyas S. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Invest. 2020 Oct 1; 130 (10):5380-5396
    View PubMed
  15. Buckarma EH, Werneburg NW, Conboy CB, Kabashima A, O'Brien DR, Wang C, Rizvi S, Smoot RL. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma. Mol Cancer Res. 2020 Oct; 18 (10):1574-1588 Epub 2020 July 09
    View PubMed
  16. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, Calvisi DF, Perugorria MJ, Fabris L, Boulter L, Macias RIR, Gaudio E, Alvaro D, Gradilone SA, Strazzabosco M, Marzioni M, Coulouarn C, Fouassier L, Raggi C, Invernizzi P, Mertens JC, Moncsek A, Rizvi S, Heimbach J, Koerkamp BG, Bruix J, Forner A, Bridgewater J, Valle JW, Gores GJ. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020 Sep; 17 (9):557-588 Epub 2020 June 30
    View PubMed
  17. Rizvi S, Gores GJ. The Two Faces of Relaxin in Cancer: Antitumor or Protumor? Hepatology 2020 Mar; 71 (3):1117-1119
    View PubMed
  18. Loeuillard E, Conboy CB, Gores GJ, Rizvi S. Immunobiology of cholangiocarcinoma. JHEP Rep. 2019 Oct; 1 (4):297-311 Epub 2019 July 10
    View PubMed
  19. Loeuillard E, Fischbach SR, Gores GJ, Rizvi S. Animal models of cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 May 1; 1865 (5):982-992 Epub 2018 Apr 05
    View PubMed
  20. Rizvi S, Gores GJ. Fibroblast Growth Factor Receptor Inhibition for Cholangiocarcinoma: Looking Through a Door Half-Opened. Hepatology 2018 Dec; 68 (6):2428-2430 Epub 2018 Nov 07
    View PubMed
  21. Kabashima A, Hirsova P, Bronk SF, Hernandez MC, Truty MJ, Rizvi S, Kaufmann SH, Gores GJ. Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma. J Hepatol. 2018 Jun; 68 (6):1228-1238 Epub 2018 Mar 09
    View PubMed
  22. Rizvi S, Eaton J, Yang JD, Chandrasekhara V, Gores GJ. Emerging Technologies for the Diagnosis of Perihilar Cholangiocarcinoma. Semin Liver Dis. 2018 May; 38 (2):160-169 Epub 2018 June 05
    View PubMed
  23. Mertens JC, Rizvi S, Gores GJ. Targeting cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018 Apr; 1864 (4 Pt B):1454-1460 Epub 2017 Aug 24
    View PubMed
  24. Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2018 Feb; 15 (2):95-111 Epub 2017 Oct 10
    View PubMed
  25. Rizvi S, Fischbach SR, Bronk SF, Hirsova P, Krishnan A, Dhanasekaran R, Smadbeck JB, Smoot RL, Vasmatzis G, Gores GJ. YAP-associated chromosomal instability and cholangiocarcinoma in mice. Oncotarget. 2018 Jan 19; 9 (5):5892-5905 Epub 2017 Dec 22
    View PubMed
  26. Anderson B, Rizvi S, Lin G, Nehra V. A case of heart failure and diarrhoea. Gut. 2017 Oct; 66 (10):1778 Epub 2016 Nov 09
    View PubMed
  27. Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017 Sep; 67 (3):632-644 Epub 2017 Apr 05
    View PubMed
  28. Rizvi S, Yang JD, Gores GJ. Anti-GP2 IgA: a biomarker for disease severity and/or cholangiocarcinoma in primary sclerosing cholangitis? Gut 2017 Jan; 66 (1):4-5 Epub 2016 Sept 01
    View PubMed
  29. Sapisochin G, Facciuto M, Rubbia-Brandt L, Marti J, Mehta N, Yao FY, Vibert E, Cherqui D, Grant DR, Hernandez-Alejandro R, Dale CH, Cucchetti A, Pinna A, Hwang S, Lee SG, Agopian VG, Busuttil RW, Rizvi S, Heimbach JK, Montenovo M, Reyes J, Cesaretti M, Soubrane O, Reichman T, Seal J, Kim PT, Klintmalm G, Sposito C, Mazzaferro V, Dutkowski P, Clavien PA, Toso C, Majno P, Kneteman N, Saunders C, Bruix J, iCCA International Consortium. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment. Hepatology. 2016 Oct; 64 (4):1178-88 Epub 2016 Aug 24
    View PubMed
  30. Rizvi S, Borad MJ. The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? J Gastrointest Oncol. 2016 Oct; 7 (5):789-796
    View PubMed
  31. Rizvi S, Yamada D, Hirsova P, Bronk SF, Werneburg NW, Krishnan A, Salim W, Zhang L, Trushina E, Truty MJ, Gores GJ. A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma. J Biol Chem. 2016 Apr 8; 291 (15):8031-47 Epub 2016 Jan 29
    View PubMed
  32. Rizvi S, Gores GJ. Liver capsule: Cholangiocarcinoma (CCA). Hepatology. 2016 Apr; 63 (4):1356 Epub 2016 Feb 01
    View PubMed
  33. Rizvi S, Yamada D, Hirsova P, Bronk S, Werneburg NW, Zhang L, Trushina E, Gores GJ. Mo1469 Fibroblast Growth Factor Receptor (FGFR) Signaling Activation Culminates in a Mcl-1 Regulated Tumor Survival Pathway in CC Gastroenterology. 2016; 150(4):S1124.
  34. Rizvi S, Eaton JE, Gores GJ. Primary Sclerosing Cholangitis as a Premalignant Biliary Tract Disease: Surveillance and Management. Clin Gastroenterol Hepatol. 2015 Nov; 13 (12):2152-65 Epub 2015 June 05
    View PubMed
  35. Yamada D, Rizvi S, Razumilava N, Bronk SF, Davila JI, Champion MD, Borad MJ, Bezerra JA, Chen X, Gores GJ. IL-33 facilitates oncogene-induced cholangiocarcinoma in mice by an interleukin-6-sensitive mechanism. Hepatology. 2015 May; 61 (5):1627-42 Epub 2015 Mar 20
    View PubMed
  36. Rizvi S, Gores GJ. Molecular Profiling and Research of Therapeutic Targets. Dig Dis. 2015; 33 (4):586-9 Epub 2015 July 06
    View PubMed
  37. Rizvi S, Borad MJ, Patel T, Gores GJ. Cholangiocarcinoma: molecular pathways and therapeutic opportunities. Semin Liver Dis. 2014 Nov; 34 (4):456-64 Epub 2014 Nov 04
    View PubMed
  38. Rizvi S, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem. 2014 Aug 15; 289 (33):22835-22849 Epub 2014 June 27
    View PubMed
  39. Hartman DJ, Krasinskas AM, Uttam S, Staton K, Bista R, Rizvi S, Slivka A, Brand R, Liu Y. Assessment of nuclear nanomorphology marker to improve the detection of malignancy from bile duct biopsy specimens. Am J Clin Pathol. 2014 Jun; 141 (6):884-91
    View PubMed
  40. Rizvi S, Gores GJ. Molecular pathogenesis of cholangiocarcinoma. Dig Dis. 2014; 32 (5):564-9 Epub 2014 July 14
    View PubMed
  41. Rizvi S, Gores GJ. Current diagnostic and management options in perihilar cholangiocarcinoma. Digestion. 2014; 89 (3):216-24 Epub 2014 May 22
    View PubMed
  42. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013 Dec; 145 (6):1215-29 Epub 2013 Oct 15
    View PubMed
  43. Fingas CD, Mertens JC, Razumilava N, Sydor S, Bronk SF, Christensen JD, Rizvi SH, Canbay A, Treckmann JW, Paul A, Sirica AE, Gores GJ. Polo-like kinase 2 is a mediator of hedgehog survival signaling in cholangiocarcinoma. Hepatology. 2013 Oct; 58(4):1362-74. Epub 2013 Aug 06.
    View PubMed
  44. Fasanella KE, Bista RK, Staton K, Rizvi S, Uttam S, Zhao C, Sepulveda A, Brand RE, McGrath K, Liu Y. Nuclear Nano-architecture Markers of Gastric Cardia and Upper Squamous Esophagus Detect Esophageal Cancer "Field Effect". J Cancer. 2013; 4: (8)626-34.
    View PubMed
  45. Lomberk G, Mathison AJ, Grzenda A, Seo S, DeMars CJ, Rizvi S, Bonilla-Velez J, Calvo E, Fernandez-Zapico ME, Iovanna J, Buttar NS, Urrutia R. Sequence-specific recruitment of heterochromatin protein 1 via interaction with Kruppel-like factor 11, a human transcription factor involved in tumor suppression and metabolic diseases. J Biol Chem. 2012 Apr 13; 287 (16):13026-39 Epub 2012 Feb 08
    View PubMed
  46. Rizvi S, Schoen RE. Supplementation with oral vs. intravenous iron for anemia with IBD or gastrointestinal bleeding: is oral iron getting a bad rap? Am J Gastroenterol. 2011 Nov; 106: (11)1872-9.
    View PubMed
  47. Rizvi S, Demars CJ, Comba A, Gainullin VG, Rizvi Z, Almada LL, Wang K, Lomberk G, Fernandez-Zapico ME, Buttar NS. Combinatorial chemoprevention reveals a novel smoothened-independent role of GLI1 in esophageal carcinogenesis. Cancer Res. 2010 Sep 1; 70 (17):6787-96 Epub 2010 July 20
    View PubMed
  48. Buttar NS, DeMars CJ, Lomberk G, Rizvi S, Bonilla-Velez J, Achra S, Rashtak S, Wang KK, Fernandez-Zapico ME, Urrutia R. Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis. J Biol Chem. 2010 Apr 9; 285 (15):11433-44 Epub 2010 Feb 12
    View PubMed
  49. Ilyas S, DeMars CJ, Buttar NS. Chemoprevention in Barrett's esophagus. J Gastrointest Cancer. 2007; 38 (1):1-9
    View PubMed
PST-20258407